Phase II Trial of Capecitabine Plus Erlotinib Versus Capecitabine Alone in Patients with Advanced Colorectal Cancer

What is it about?

EGFR-TKIs were thought to be ineffective in advanced colorectal cancer. It is now known EGFR mAb only provide benefit in patients with RAS wildtype tumours from a left-sided primary. Our previously unpublished negative study of erlotinib, an EGFR-TKI, in advanced colorectal cancer has been re-examined in the unplanned subgroups, and appears to show a trend towards benefit in these subgroups. Thus supporting further research into EGFR-TKIs in RAS wildtype left-sided advanced colorectal cancer.

Featured Image